| Cardio-oncology: progress in diagnosis and treatment of cardiac dysfunction. J Tromp, LC Steggink, DJ Van Veldhuisen, JA Gietema, P Van der Meer Clinical pharmacology and therapeutics 101 (4), 481-490, 2017 | 42 | 2017 |
| Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years JN Jacobse, LC Steggink, GS Sonke, M Schaapveld, YM Hummel, ... European journal of heart failure 22 (2), 338-346, 2020 | 31 | 2020 |
| Cardiac Function After Radiation Therapy for Breast Cancer VAB van den Bogaard, P van Luijk, YM Hummel, P van der Meer, E Schuit, ... International Journal of Radiation Oncology* Biology* Physics 104 (2), 392-400, 2019 | 28 | 2019 |
| Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy J Stelwagen, S Lubberts, LC Steggink, G Steursma, LM Kruyt, ... British journal of cancer 123 (11), 1599-1607, 2020 | 27 | 2020 |
| High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a … TG Steenbruggen, LC Steggink, CM Seynaeve, JJM van der Hoeven, ... JAMA oncology, 2020 | 17 | 2020 |
| Physical activity and cardiac function in long-term breast cancer survivors: a cross-sectional study WR Naaktgeboren, WG Groen, JN Jacobse, LC Steggink, ... Cardio Oncology 4 (2), 183-191, 2022 | 15 | 2022 |
| Survival in anaplastic thyroid cancer in relation to pre-existing goiter: a population-based study LC Steggink, BAC van Dijk, TP Links, JTM Plukker The American Journal of Surgery 209 (6), 1013-1019, 2015 | 13 | 2015 |
| Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy LC Steggink, H Boer, C Meijer, JD Lefrandt, LWMM Terstappen, ... The pharmacogenomics journal 21 (2), 152-164, 2021 | 7 | 2021 |
| Insulin‐like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β‐hCG and cancer treatment LC Steggink, AP van Beek, H Boer, C Meijer, S Lubberts, SF Oosting, ... Andrology 7 (4), 441-448, 2019 | 6 | 2019 |
| Life expectancy 20 years after cisplatin-based treatment for testicular cancer (TC). S Lubberts, LM Kruyt, LC Steggink, G Steursma, J Nuver, S Oosting, ... Journal of Clinical Oncology 35 (15_suppl), 4550-4550, 2017 | 4 | 2017 |
| Vascular damage and pulmonary function in very long-term survivors of testicular cancer (TC) treated with cisplatin-based chemotherapy (CT) J Stelwagen, S Lubberts, LC Steggink, G Steursma, LM Kruyt, ... Annals of Oncology 29, viii324, 2018 | 2 | 2018 |
| Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors A van Ommen-Nijhof, JN Jacobse, LC Steggink, JD Lefrandt, JA Gietema, ... Breast Cancer Research and Treatment 196 (3), 591-602, 2022 | 1 | 2022 |
| Prognostic Factors and Survival in Anaplastic Thyroid Cancer: A Population-based Study in North-East Netherlands JT Plukker, L Steggink, B Van Dijk Annals of Surgical Oncology 20, S85, 2013 | 1 | 2013 |
| A woman with skin abnormalities and muscle weakness LC Steggink, ME Hettema, CE Delsing Nederlands tijdschrift voor geneeskunde 157 (30), A6306-A6306, 2013 | 1 | 2013 |
| Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer. L De Boo, J Quist, M Opdam, K Jozwiak, P Gazinska, D Peters, ... Journal of Clinical Oncology 40 (16_suppl), 541-541, 2022 | | 2022 |
| Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors AVO Nijhof, JN Jacobse, LC Steggink, JD Lefrandt, JA Gietema, ... | | 2022 |
| Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors WR Naaktgeboren, WG Groen, JN Jacobse, LC Steggink, ... | | 2022 |
| Long-term outcome and treatment-related toxicity in patients with breast and testicular cancer L Steggink | | 2022 |
| High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer—Reply TG Steenbruggen, LC Steggink, GS Sonke JAMA oncology 6 (8), 1300-1300, 2020 | | 2020 |
| High-dose chemotherapy (HDCT) with hematopoietic stem cell transplantation (HSCT) in high-risk breast cancer (BC) patients with≥ 4 involved axillary lymph nodes (ALN): 20-year … TG Steenbruggen, LC Steggink, CM Seynaeve, JJM van der Hoeven, ... Annals of Oncology 29, viii59, 2018 | | 2018 |
Gietema JAProfessor of Medical Oncology, University Medical Center GroningenVerified email at umcg.nl
